BOOK
United States Skin Disease Needs Assessment, An Issue of Dermatologic Clinics - E-Book
(2012)
Additional Information
Book Details
Abstract
This issue discusses the concerns of skin disease in the United States and the national clinical dermatology research priorities – the article topics also closely follow the plan set out by the recent dermatology needs assessment of the UK. Articles include Health Care Disparities, The Burden of Skin Disease in the United States, as well as specific conditions such as psoriasis, acne, and melanoma. There is also an article devoted to dermatologic surgery needs assessment.
Table of Contents
Section Title | Page | Action | Price |
---|---|---|---|
Front Cover | 1 | ||
Dermatologic Clinics | 2 | ||
Copyright Page | 3 | ||
Table of Contents | 8 | ||
Contributors | 4 | ||
Dermatologic Clinics | 12 | ||
Preface | 14 | ||
Dedication | 16 | ||
Chapter 1. Introduction: US Dermatologic Health Care Needs Assessment | 18 | ||
HEALTH CARE NEEDS ASSESSMENT | 18 | ||
SKIN DISEASE | 18 | ||
HEALTH CARE NEED | 19 | ||
WHAT TO EXPECT IN THIS USSKIN DISEASE NEEDS ASSESSMENT | 19 | ||
REFERENCES | 20 | ||
Chapter 2. The Burden of Skin Disease in the United States and Canada | 22 | ||
SKIN DISEASE CLASSIFICATION | 22 | ||
EPIDEMIOLOGY | 23 | ||
QUALITY OF LIFE | 27 | ||
COSTS OF SKIN DISEASE | 28 | ||
SUMMARY | 32 | ||
REFERENCES | 32 | ||
Chapter 3. Services Available and Their Effectiveness | 36 | ||
FOUR LEVELS OF HEALTH CARE PROVIDERS | 37 | ||
WHERE SERVICES ARE PROVIDED | 40 | ||
WHAT SERVICES ARE PROVIDED | 41 | ||
EFFICACY OF TREATMENT OR CARE | 47 | ||
REFERENCES | 52 | ||
Chapter 4. Models of Care and Organization of Services | 56 | ||
PPOs AND DERMATOLOGY | 58 | ||
AREAS FOR IMPROVEMENT: PPOS AND DERMATOLOGY | 59 | ||
THE VHA | 59 | ||
ACCESS TO DERMATOLOGY CARE | 61 | ||
OUTCOMES OF HMO VERSUS FFS | 61 | ||
IMPROVING DERMATOLOGY CARE | 62 | ||
SUPPLY AND DEMAND | 62 | ||
INCREASING PATIENT AWARENESS | 63 | ||
INCREASING TRAINING OF NONDERMATOLOGISTS | 63 | ||
PHYSICIAN EXTENDERS | 63 | ||
WAIT TIMES | 64 | ||
MALPRACTICE | 65 | ||
ROLE OF PHARMACEUTICALS | 65 | ||
SUMMARY | 66 | ||
REFERENCES | 66 | ||
Chapter 5. Dermatologic Health Disparities | 70 | ||
RACE AND ETHNICITY | 70 | ||
SKIN CANCER | 71 | ||
ATOPIC DERMATITIS | 71 | ||
HEALTH CARE REFORM AND THEDERMATOLOGY WORKFORCE | 71 | ||
DERMATOLOGY EDUCATION AND HEALTH DISPARITIES | 72 | ||
DISPARITIES IN RESEARCH | 73 | ||
SUMMARY | 73 | ||
REFERENCES | 74 | ||
Chapter 6. A Review of Health Outcomes in Patients with Psoriasis | 78 | ||
PSORIASIS SUBTYPES | 78 | ||
BURDEN OF PSORIASIS | 79 | ||
PSORIASIS COMORBIDITIES | 79 | ||
TREATMENTS | 81 | ||
SERVICES AVAILABLE | 85 | ||
SUMMARY | 85 | ||
REFERENCES | 86 | ||
Chapter 7. Health Outcomesin Atopic Dermatitis | 90 | ||
PREVALENCE AND INCIDENCE OF ATOPIC DERMATITIS | 90 | ||
ASSESSMENT OF HEALTH OUTCOMES IN A TOPIC DERMATITIS | 90 | ||
RESULTS OF HEALTH OUTCOMES IN ATOPIC DERMATITIS | 92 | ||
TREATMENT OF ATOPIC DERMATITIS AND ITS EFFECT ON HEALTH OUTCOMES | 93 | ||
REFERENCES | 98 | ||
Chapter 8. Contact Dermatitis in the United States: Epidemiology, Economic Impact, and Workplace Prevention | 104 | ||
RISK FACTORS | 106 | ||
INCIDENCE AND PREVALENCE | 108 | ||
ECONOMIC IMPACT AND COST TO SOCIETY | 109 | ||
BURDEN OF DISEASE ON THE PATIENT | 110 | ||
PREVENTION STRATEGIES | 111 | ||
PATCH TESTING | 112 | ||
SUMMARY | 113 | ||
REFERENCES | 113 | ||
Chapter 9. Acne Vulgaris: Pathogenesis, Treatment, and Needs Assessment | 116 | ||
EPIDEMIOLOGY | 116 | ||
PATHOGENESIS | 117 | ||
PREVENTION | 117 | ||
TREATMENT | 118 | ||
ACNE SCARRING | 119 | ||
BURDEN OF TREATMENT | 119 | ||
AVAILABLE SERVICES | 119 | ||
FUTURE DIRECTIONS | 120 | ||
SUMMARY | 121 | ||
REFERENCES | 121 | ||
Chapter 10. US Skin Disease Assessment: Ulcer and Wound Care | 124 | ||
VLU | 124 | ||
DFU | 125 | ||
PRU | 126 | ||
CHRONIC ULCERS: THE MANAGEMENT TEAM | 127 | ||
CHRONIC ULCER: GUIDELINES TO CARE | 127 | ||
REFERENCES | 127 | ||
Chapter 11. Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes | 130 | ||
EPIDEMIOLOGY | 130 | ||
ETIOLOGY | 131 | ||
CLINICAL PRESENTATION | 133 | ||
DIAGNOSIS | 134 | ||
PREVENTION | 136 | ||
TREATMENT | 136 | ||
PROGNOSIS | 137 | ||
NEEDS IN MELANOMA DETECTION AND CARE | 137 | ||
SUMMARY | 138 | ||
ACKNOWLEDGMENTS | 138 | ||
REFERENCES | 138 | ||
Chapter 12. Nonmelanoma Skin Cancer | 142 | ||
EPIDEMIOLOGY OF NMSCS | 142 | ||
HEALTH OUTCOMES OF NMSCs | 147 | ||
TREATMENT GUIDELINES FOR NMSCS IN THE UNITED STATES | 150 | ||
CURRENT NEEDS IN NMSC RESEARCH | 151 | ||
REFERENCES | 153 | ||
Chapter 13. Infectious Skin Diseases: A Review and Needs Assessment | 158 | ||
BACTERIAL SKIN DISEASES | 158 | ||
FUNGAL SKIN DISEASES | 160 | ||
VIRAL SKIN DISEASES | 163 | ||
SUMMARY | 165 | ||
REFERENCES | 165 | ||
Chapter 14. Needs Assessment for General Dermatologic Surgery | 170 | ||
CRYOSURGERY | 171 | ||
ELECTROSURGERY | 172 | ||
PHOTODYNAMIC THERAPY | 173 | ||
EXCISIONS | 175 | ||
OTHER TOPICS | 178 | ||
SUMMARY | 179 | ||
REFERENCES | 180 | ||
Chapter 15. Needs Assessment for Mohs Micrographic Surgery | 184 | ||
INDICATIONS | 184 | ||
UTILIZATION | 186 | ||
USE OF CURETTAGE BEFORE MOHS | 186 | ||
USE OF PROPHYLACTIC ANTIBIOTICS | 187 | ||
MANAGING ANTICOAGULANTS | 188 | ||
OUTCOMES | 188 | ||
SUMMARY | 190 | ||
REFERENCES | 190 | ||
Chapter 16. Needs Assessment for Cosmetic Dermatologic Surgery | 194 | ||
DEFINITIONS AND BOUNDARIES | 195 | ||
COMMON INDICATIONS | 195 | ||
COMPARATIVE EFFECTIVENESS AND SAFETY | 195 | ||
SITE OF SERVICE | 195 | ||
TOPIC AREAS | 197 | ||
SUMMARY | 200 | ||
REFERENCES | 201 | ||
Chapter 17. Conclusions and Recommendations: United States Dermatologic Health Care Need Assessment | 206 | ||
SUMMARY | 206 | ||
REFERENCES | 211 | ||
Index | 212 |